Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market - 2024-2033
The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market was valued at US$ 14.12 billion in 2024 and is anticipated to reach US$ 22.34 billion by 2033, at a CAGR of 0.059 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market.
This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market Scope:
By Type
This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market.
This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market Scope:
By Type
- VEGF-A
- VEGF-B
- VEGF-C
- VEGF-D
- Tyrosine Kinase Inhibitor (TKI)
- Monoclonal Antibody
- Advanced Renal Cell Carcinoma
- Advanced Colorectal Cancer
- Metastatic Colorectal Cancer (mCRC)
- Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Recurrent Glioblastoma (rGBM)
- Ovarian Cancer (OC)
- Hepatocellular Carcinoma
- Thyroid cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Wet Age-Related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
- Retinal Vein Occlusion (RVO)
- Others
- Oral
- Intravenous
- Intravitreal
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Pfizer Inc.
- Biocon
- Exelixis, Inc.
- Bayer AG
- Eisai Co., Ltd.
- Takeda Pharmaceuticals U.S.A., Inc.
- Sanofi (Regeneron Pharmaceuticals, Inc.)
- AVEO Pharmaceuticals, Inc.
- Eli Lilly and Company
- Genentech USA, Inc.
This report delivers a comprehensive overview of the Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market. The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence and Prevalence of Cancer
4.1.1.2. Advancements in Drug Development & Biosimilars
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Adverse Side Effects Associated with the Treatment
4.1.2.3. XX
4.1.3. Opportunity
4.1.3.1. Technological Advancements and Combination Therapies
4.1.3.2. XX
5. IMPACT ANALYSIS
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest selling Brand
6.1.3. Market leaders with established Product
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Case Studies/Ongoing Research
6.5. Regulatory and Reimbursement Landscape
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East & Africa
6.6. Porter’s Five Forces Analysis
6.7. Supply Chain Analysis
6.8. Patent Analysis
6.9. SWOT Analysis
6.10. Unmet Needs and Gaps
6.11. Recommended Strategies for Market Entry and Expansion
6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.13. Pricing Analysis and Price Dynamics
6.14. Key Opinion Leaders
7. BY TYPE
7.1. Introduction
7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index By Type
7.2. VEGF-A*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. VEGF-B
7.4. VEGF-C
7.5. VEGF-D
8. BY DRUG TYPE
8.1. Introduction
8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index By Drug Type
8.2. Tyrosine Kinase Inhibitor (TKI)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Pazopanib
8.2.4. Sunitinib Malate
8.2.5. Cabozantinib
8.2.6. Sorafenib
8.2.7. Lenvatinib
8.2.8. Regorafenib
8.2.9. Axitinib
8.2.10. Ponatinib
8.2.11. Tivozanib
8.2.12. Others
8.3. Monoclonal Antibody
8.3.1. Bevacizumab
8.3.2. Brolucizumab
8.3.3. Ramucirumab
8.3.4. Ranibizumab
8.3.5. Faricimab
8.3.6. Others
9. BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index By Application
9.2. Advanced Renal Cell Carcinoma*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Advanced Colorectal Cancer
9.4. Metastatic Colorectal Cancer (mCRC)
9.5. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
9.6. Recurrent Glioblastoma (rGBM)
9.7. Ovarian Cancer (OC)
9.8. Hepatocellular Carcinoma
9.9. Thyroid cancer
9.10. Non-Small Cell Lung Cancer (NSCLC)
9.11. Wet Age-Related Macular Degeneration (AMD)
9.12. Diabetic Macular Edema (DME)
9.13. Retinal Vein Occlusion (RVO)
9.14. Others
10. BY ROUTE OF ADMINISTRATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Intravenous
10.4. Intravitreal
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Mexico
11.4.7.2. Brazil
11.4.7.3. Argentina
11.4.7.4. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. South Korea
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Novartis AG*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
13.1.3. Financial Overview
13.1.3.1. Company Revenue’s
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.5. SWOT Analysis
13.2. F. Hoffmann-La Roche Ltd
13.3. Amgen Inc.
13.4. Pfizer Inc.
13.5. Biocon
13.6. Exelixis, Inc.
13.7. Bayer AG
13.8. Eisai Co., Ltd.
13.9. Takeda Pharmaceuticals U.S.A., Inc.
13.10. Sanofi (Regeneron Pharmaceuticals, Inc.)
13.11. AVEO Pharmaceuticals, Inc.
13.12. Eli Lilly and Company
13.13. Genentech USA, Inc. (LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence and Prevalence of Cancer
4.1.1.2. Advancements in Drug Development & Biosimilars
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Adverse Side Effects Associated with the Treatment
4.1.2.3. XX
4.1.3. Opportunity
4.1.3.1. Technological Advancements and Combination Therapies
4.1.3.2. XX
5. IMPACT ANALYSIS
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest selling Brand
6.1.3. Market leaders with established Product
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Case Studies/Ongoing Research
6.5. Regulatory and Reimbursement Landscape
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East & Africa
6.6. Porter’s Five Forces Analysis
6.7. Supply Chain Analysis
6.8. Patent Analysis
6.9. SWOT Analysis
6.10. Unmet Needs and Gaps
6.11. Recommended Strategies for Market Entry and Expansion
6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.13. Pricing Analysis and Price Dynamics
6.14. Key Opinion Leaders
7. BY TYPE
7.1. Introduction
7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index By Type
7.2. VEGF-A*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. VEGF-B
7.4. VEGF-C
7.5. VEGF-D
8. BY DRUG TYPE
8.1. Introduction
8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index By Drug Type
8.2. Tyrosine Kinase Inhibitor (TKI)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Pazopanib
8.2.4. Sunitinib Malate
8.2.5. Cabozantinib
8.2.6. Sorafenib
8.2.7. Lenvatinib
8.2.8. Regorafenib
8.2.9. Axitinib
8.2.10. Ponatinib
8.2.11. Tivozanib
8.2.12. Others
8.3. Monoclonal Antibody
8.3.1. Bevacizumab
8.3.2. Brolucizumab
8.3.3. Ramucirumab
8.3.4. Ranibizumab
8.3.5. Faricimab
8.3.6. Others
9. BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index By Application
9.2. Advanced Renal Cell Carcinoma*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Advanced Colorectal Cancer
9.4. Metastatic Colorectal Cancer (mCRC)
9.5. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
9.6. Recurrent Glioblastoma (rGBM)
9.7. Ovarian Cancer (OC)
9.8. Hepatocellular Carcinoma
9.9. Thyroid cancer
9.10. Non-Small Cell Lung Cancer (NSCLC)
9.11. Wet Age-Related Macular Degeneration (AMD)
9.12. Diabetic Macular Edema (DME)
9.13. Retinal Vein Occlusion (RVO)
9.14. Others
10. BY ROUTE OF ADMINISTRATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Intravenous
10.4. Intravitreal
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Mexico
11.4.7.2. Brazil
11.4.7.3. Argentina
11.4.7.4. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. South Korea
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Novartis AG*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
13.1.3. Financial Overview
13.1.3.1. Company Revenue’s
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.1.4.1. Mergers & Acquisitions
13.1.4.2. Key Product Development Activities
13.1.4.3. Regulatory Approvals, etc.
13.1.5. SWOT Analysis
13.2. F. Hoffmann-La Roche Ltd
13.3. Amgen Inc.
13.4. Pfizer Inc.
13.5. Biocon
13.6. Exelixis, Inc.
13.7. Bayer AG
13.8. Eisai Co., Ltd.
13.9. Takeda Pharmaceuticals U.S.A., Inc.
13.10. Sanofi (Regeneron Pharmaceuticals, Inc.)
13.11. AVEO Pharmaceuticals, Inc.
13.12. Eli Lilly and Company
13.13. Genentech USA, Inc. (LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
